AstraZeneca has completed the sale of the US rights for its gastrointestinal drug Entocort (budesonide) to Perrigo for $380m.
Entocort is a gastroenterology medicine indicated to treat patients with mild to moderate Crohn’s disease (CD).
The sale is part of the company’s plan to focus on three main therapy areas as the drug is outside its focus area.
Upon completion of the deal, Perrigo paid AstraZeneca $380m to acquire the rights to sell Entocort capsules and the authorised generic Entocort capsules marketed by Par Pharmaceuticals.
The deal does not include the transfer of any AstraZeneca employees or plants.
In capsule formulation, Entocort is a first-line therapy indicated for the induction and maintenance of clinical remission of mild to moderate active Crohn’s disease featuring the ileum and/or the ascending colon.
As an enema, Entocort is indicated to induct and maintain clinical remission of distal ulcerative colitis in the rectum, sigmoid colon and descending colon.
In July, the company divested global rights of Entocort outside the US to Tillotts Pharma, part of the Zeria Group for $215m.
The drug is currently approved for use in more than 40 countries to treat CD, as well as ulcerative colitis (UC) in certain markets.
Both CD and UC are types of inflammatory bowel disease (IBD), which is one of the most prevalent gastrointestinal (GI) diseases, affecting more than 2.2 million people in Europe and around five million worldwide.
Image: AstraZeneca headquarters in London, UK. Photo: courtesy of AstraZeneca plc.